Cargando…

Scale-Up of an Human Papillomavirus Testing Implementation Program in El Salvador

OBJECTIVE: The Cervical Cancer Prevention in El Salvador is a demonstration project to introduce a lower-cost human papillomavirus (HPV)-DNA test into a public sector project. Started in October 2012, The Cervical Cancer Prevention in El Salvador consists of 3 phases and will ultimately screen 30,00...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cremer, Miriam, Maza, Mauricio, Alfaro, Karla, Morales Velado, Mario, Felix, Juan, Castle, Philip E., Kim, Jane, Gage, Julia C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2017
Materias:	Original Research Articles: Cervix and HPV
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5201413/ https://www.ncbi.nlm.nih.gov/pubmed/27922905 http://dx.doi.org/10.1097/LGT.0000000000000280

Ejemplares similares

Introducing a High-Risk HPV DNA Test Into a Public Sector Screening Program in El Salvador
por: Cremer, Miriam L., et al.
Publicado: (2016)

Risks of CIN 2+, CIN 3+, and Cancer by Cytology and Human Papillomavirus Status: The Foundation of Risk-Based Cervical Screening Guidelines
por: Demarco, Maria, et al.
Publicado: (2017)

Cervical cancer prevention in El Salvador (CAPE)—An HPV testing-based demonstration project: Changing the secondary prevention paradigm in a lower middle-income country
por: Maza, Mauricio, et al.
Publicado: (2017)

The cost-effectiveness of implementing HPV testing for cervical cancer screening in El Salvador
por: Campos, Nicole G., et al.
Publicado: (2019)

Statistical Modeling for Quality Assurance of Human Papillomavirus DNA Batch Testing
por: Beylerian, Emily N., et al.
Publicado: (2018)

Outcomes for Step-Wise Implementation of a Human Papillomavirus Testing–Based Cervical Screen-and-Treat Program in El Salvador
por: Alfaro, Karla, et al.
Publicado: (2020)

Low Risk of Cervical Cancer/Precancer Among Most Women Under Surveillance Postcolposcopy
por: Demarco, Maria, et al.
Publicado: (2018)

Human papillomavirus (HPV) vaccines in adults: Learnings from long-term follow-up of quadrivalent HPV vaccine clinical trials
por: Goldstone, Stephen E.
Publicado: (2023)

Human papillomavirus vaccination at the first opportunity: An overview
por: Bednarczyk, Robert A., et al.
Publicado: (2023)

Epidemiology of human papillomavirus on condyloma acuminatum in Shandong Province，China
por: Yuan, Haowen, et al.
Publicado: (2023)

Prevalence and human papillomavirus (HPV) genotype distribution in Suzhou, China
por: Wang, Tianyu, et al.
Publicado: (2023)

Human papillomavirus vaccine effectiveness by age at vaccination: A systematic review
por: Ellingson, Mallory K., et al.
Publicado: (2023)

Digital Colposcopy With Dynamic Spectral Imaging for Detection of Cervical Intraepithelial Neoplasia 2+ in Low-Grade Referrals: The IMPROVE-COLPO Study
por: Cholkeri-Singh, Aarathi, et al.
Publicado: (2018)

Outcomes of Conservative Management of High Grade Squamous Intraepithelial Lesions in Young Women
por: Lee, Marette H., et al.
Publicado: (2018)

Importance of Colposcopy Impression in the Early Diagnosis of Posthysterectomy Vaginal Cancer
por: Cong, Qing, et al.
Publicado: (2019)

Impact of Age at Conization on Obstetrical Outcome: A Case-Control Study
por: Chevreau, Julien, et al.
Publicado: (2017)

Barriers and facilitators in uptake of human papillomavirus vaccine across English Canada: A review
por: Khan, Amal, et al.
Publicado: (2023)

Myasthenia gravis after the third dose of human papillomavirus 9-valent vaccine: A case report
por: Ding, Yuan, et al.
Publicado: (2023)

Parents’ willingness to vaccinate their daughters with human papillomavirus vaccine and associated factors in Debretabor town, Northwest Ethiopia: A community-based cross-sectional study
por: Aragaw, Getie Mihret, et al.
Publicado: (2023)

An investigation on cervical cancer and human papillomavirus vaccine knowledge, and analysis of influencing factors for choosing domestic or imported 2vHPV vaccine among females in Shenzhen, China
por: Chen, Linxiang, et al.
Publicado: (2023)

Implementing interventions to start HPV vaccination at age 9: Using the evidence we have
por: Brandt, Heather M., et al.
Publicado: (2023)

Health impact and cost-effectiveness of implementing gender-neutral vaccination with the 9-valent HPV vaccine in Hong Kong
por: Cheung, Tak Hong, et al.
Publicado: (2023)

Evaluation of a Cervicography-Based Program to Ensure Quality of Visual Inspection of the Cervix in HIV-Infected Women in Johannesburg, South Africa
por: Firnhaber, Cynthia, et al.
Publicado: (2015)

The association of initiating HPV vaccination at ages 9–10 years and up-to-date status among adolescents ages 13–17 years, 2016-2020
por: Minihan, Adair K., et al.
Publicado: (2023)

Factors affecting attendance to cervical cancer screening among women in the Paracentral Region of El Salvador: a nested study within the CAPE HPV screening program
por: Alfaro, Karla M., et al.
Publicado: (2015)

Medical ethics principles underscore advocating for human papillomavirus vaccine
por: Healy, C. Mary, et al.
Publicado: (2022)

Cervical Cancer Prevention in El Salvador: Gains to Date and Challenges for the Future
por: Alfaro, Karla, et al.
Publicado: (2022)

Resumption of active recommendation of the human papillomavirus vaccine in Japan and future challenges for the National Immunization Program
por: Ujiie, Mugen
Publicado: (2022)

Social and psychological impact of HPV testing in cervical screening: a qualitative study
por: McCaffery, K, et al.
Publicado: (2006)

AN UPWARD TREND IN DNA P16INK4A METHYLATION PATTERN AND HIGH RISK HPV INFECTION ACCORDING TO THE SEVERITY OF THE CERVICAL LESION
por: Carestiato, Fernanda Nahoum, et al.
Publicado: (2013)

Engaging health plans to prioritize HPV vaccination and initiate at age 9
por: Foley, Shaylen, et al.
Publicado: (2023)

Framing of national HPV vaccine recommendations and willingness to recommend at ages 9-10
por: Kahn, Benjamin Z., et al.
Publicado: (2023)

HPV vaccine initiation at 9 or 10 years of age and better series completion by age 13 among privately and publicly insured children in the US
por: Saxena, Kunal, et al.
Publicado: (2023)

Post-marketing surveillance study of the safety of the HPV-16/18 vaccine in Korea (2017–2021)
por: Eun, Byung-Wook, et al.
Publicado: (2023)

Optimizing timing of adolescent vaccines: Impact of initiating HPV vaccination before Tdap or meningococcal vaccination on timely completion of the HPV vaccine series
por: Kajtezovic, Sidika, et al.
Publicado: (2023)

Does HPV vaccination initiation at age 9, improve HPV initiation and vaccine series completion rates by age 13?
por: O’Leary, Sonja C., et al.
Publicado: (2023)

HPV vaccine recommendations by age: A survey of providers in federally qualified health centers
por: Lake, Paige, et al.
Publicado: (2023)

Feminized vaccine? Parents’ attitudes toward HPV vaccination of adolescents in Poland: A representative study
por: Sobierajski, Tomasz, et al.
Publicado: (2023)

Successful treatment of anogenital warts with single dose Bacillus Calmette Guerin vaccine without prior sensitization in tuberculosis endemic country: Two case report
por: Achdiat, Pati Aji, et al.
Publicado: (2023)

Willingness to get HPV vaccination among female university students in Kuwait and its relation to vaccine conspiracy beliefs
por: Alsanafi, Mariam, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_2tg21ve8pif3qcs9gk4g3th887